Statins for cardiovascular prevention according to different strategies: a cost analysis.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_58200D377846
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Statins for cardiovascular prevention according to different strategies: a cost analysis.
Périodique
American Journal of Cardiovascular Drugs
Auteur(s)
Ito M.K., Nanchen D., Rodondi N., Paccaud F., Waeber G., Vollenweider P., Marques-Vidal P.
ISSN
1175-3277[print]
ISSN-L
1175-3277[linking]
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
11
Numéro
1
Pages
33-44
Langue
anglais
Résumé
Background: Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce coronary heart disease (CHD) rates. However, the cost effectiveness of statin treatment in the primary prevention of CHD has not been fully established. Objective: To estimate the costs of CHD prevention using statins in Switzerland according to different guidelines, over a 10-year period. Methods: The overall 10-year costs, costs of one CHD death averted, and of 1 year without CHD were computed for the European Society of Cardiology (ESC), the International Atherosclerosis Society (IAS), and the US Adult Treatment Panel III (ATP-III) guidelines. Sensitivity analysis was performed by varying number of CHD events prevented and costs of treatment. Results: Using an inflation rate of medical costs of 3%, a single yearly consultation, a single total cholesterol measurement per year, and a generic statin, the overall 10-year costs of the ESC, IAS, and ATP-III strategies were 2.2, 3.4, and 4.1 billion Swiss francs (SwF [SwF1 = $US0.97]). In this scenario, the average cost for 1 year of life gained was SwF352, SwF421, and SwF485 thousand, respectively, and it was always higher in women than in men. In men, the average cost for 1 year of life without CHD was SwF30.7, SwF42.5, and SwF51.9 thousand for the ESC, IAS, and ATP-III strategies, respectively, and decreased with age. Statin drug costs represented between 45% and 68% of the overall preventive cost. Changing the cost of statins, inflation rates, or number of fatal and non-fatal cases of CHD averted showed ESC guidelines to be the most cost effective. Conclusion: The cost of CHD prevention using statins depends on the guidelines used. The ESC guidelines appear to yield the lowest costs per year of life gained free of CHD.
Mots-clé
Colaus Study , Adult , Aged , Coronary Disease/economics* , Coronary Disease/prevention & control* , Cost-Benefit Analysis , Costs and Cost Analysis , Female , General Practice , Health Care Costs , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/economics* , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use* , Male , Middle Aged , Practice Guidelines as Topic
Pubmed
Web of science
Création de la notice
16/02/2011 13:35
Dernière modification de la notice
20/08/2019 15:11
Données d'usage